ReturnTo Theme-Group-Choice | Onelevelup |
4H045 | PEPTIDES OR PROTEINS | |
C07K1/00 -19/00 |
C07K1/00-19/00 | AA | AA00 TYPE OF INVENTION |
AA10 | |||||||||
. Substances | ||||||||||||
AA11 | AA20 | |||||||||||
. . Antigens or antibodies | . Processes of preparation | |||||||||||
AA30 | ||||||||||||
. Use | ||||||||||||
AA40 | ||||||||||||
. Apparatus | ||||||||||||
AA50 | ||||||||||||
. Others | ||||||||||||
BA | BA00 CHEMICAL CONSTITUTION |
BA01 | BA05 | BA09 | BA10 | |||||||
. containing D-alpha-amino acids | . characterised by three-dimensional structure | . having known amino acid compositions | . The number of alpha-amino acids | |||||||||
BA11 | BA12 | BA13 | BA14 | BA15 | BA16 | BA17 | BA18 | BA19 | BA20 | |||
. . 2 | . . 3 | . . 4-5 | . . 6-7 | . . 8-10 | . . 11-14 | . . 15-23 | . . 24-35 | . . 36-50 | . . 51-70 | |||
BA21 | BA30 | |||||||||||
. . 71-100 | . Cyclic peptides | |||||||||||
BA31 | BA32 | BA33 | BA34 | BA35 | BA40 | |||||||
. . having rings including bonds other than peptide bonds | . . . Sulfur-sulfur (S-S) bonds | . . . Ester bonds | . . . Amide bonds | . . having rings of only peptide bonds | . Conjugates of heterologous proteins or peptides | |||||||
BA41 | BA42 | BA50 | ||||||||||
. . Fusion proteins | . . bonded with carriers comprising proteins | . having characteristic constituents | ||||||||||
BA51 | BA52 | BA53 | BA54 | BA55 | BA56 | BA57 | BA60 | |||||
. . Heterocyclic compounds | . . Organometallic compounds | . . Sugars or polysaccharides | . . Nucleotides or nucleic acids | . . Steroids or lipids | . . Macromolecular compounds | . . . Polyalkylene glycols | . . Immobilised carriers | |||||
BA61 | BA62 | BA63 | BA70 | |||||||||
. . . Natural macromolecules | . . . Synthetic macromolecules | . . . Inorganic compounds | . . Pigments | |||||||||
BA71 | BA72 | |||||||||||
. . Radioactive components | . . Toxins or chemical agents | |||||||||||
CA | CA00 ORIGIN |
CA01 | CA02 | CA03 | CA04 | CA05 | CA10 | |||||
. Viruses | . . Hepatitis viruses | . . Herpes viruses | . . Leukemia viruses | . . Human immunodeficiency viruses | . Fungi or lichens | |||||||
CA11 | CA15 | CA20 | ||||||||||
. . Bacteria or actinomycetales | . . True fungi | . Protozoa | ||||||||||
CA21 | CA22 | CA30 | ||||||||||
. . Coccidia | . . Plasmodia | . Plants | ||||||||||
CA31 | CA32 | CA33 | CA40 | |||||||||
. . Cereals | . . . Wheat varieties | . . Beans | . Mammals or birds | |||||||||
CA41 | CA42 | CA43 | CA44 | CA45 | CA46 | CA50 | ||||||
. . Tumour cells | . . Bloods | . . Milks | . . Urines or urinary organs | . . Nerves or brains | . . Placentas or amniotic fluids | . Other animals | ||||||
CA51 | CA52 | CA53 | ||||||||||
. . Insects | . . Fishes | . . Reptiles or amphibians | ||||||||||
DA | DA00 PEPTIDE OR PROTEIN CHARACTERISED BY FUNCTION |
DA01 | DA02 | DA03 | DA04 | DA05 | DA10 | |||||
. Cytokines | . . Interleukins | . . . Interleukin-1 | . . . Interleukin-2 | . . . Interleukin-3 | . . Colony-stimulating factors | |||||||
DA11 | DA12 | DA13 | DA14 | DA15 | DA16 | DA17 | DA18 | DA20 | ||||
. . . Granulocyte-colony stimulating factors (G-CSFs) | . . . Granulocyte-macrophage colony stimulating factors (GM-CSFs) | . . Erythropoietins | . . Tumour necrosis factors or lymphotoxins | . . Interferons | . . . Alpha-interferons | . . . Beta-interferons | . . . Gamma-interferons | . . Epidermal growth factors | ||||
DA21 | DA22 | DA30 | ||||||||||
. . Nerve growth factors | . . Tumour growth factors | . Hormones | ||||||||||
DA31 | DA32 | DA33 | DA34 | DA35 | DA36 | DA37 | DA38 | |||||
. . Growth hormones | . . Natriuretic peptides | . . Opioid peptides | . . Oxytocins or vasopressins | . . Somatostatins | . . Calcitonins | . . Insulins | . . Insulin-like growth factors or somatomedins | |||||
DA45 | DA46 | DA47 | DA50 | |||||||||
. Hormone-releasing or hormone-inhibiting factors | . . Growth hormone-releasing factors | . . Luteinising hormone-releasing hormones | . Receptors or cell surface proteins | |||||||||
DA51 | DA55 | DA56 | DA57 | DA58 | ||||||||
. . Receptors of cytokines | . Enzyme inhibitors | . . Protease inhibitors | . . . Angiotensin converting enzyme inhibitors | . . . Renin inhibitors | ||||||||
DA65 | DA66 | DA70 | ||||||||||
. Blood coagulation factors | . . Factors VIII | . Albumins | ||||||||||
DA75 | DA76 | DA80 | ||||||||||
. Immunoglobulins or antibodies | . . Monoclonal antibodies | . Lectins | ||||||||||
DA83 | DA86 | DA89 | ||||||||||
. Toxins e.g. protein synthesis inhibitors | . Antigens | . Enzymes | ||||||||||
EA | EA00 USE |
EA01 | EA02 | EA05 | EA06 | EA07 | ||||||
. Foods or brewing | . . Sweeteners | . Agriculture forestry and fishery industries | . . Insecticides or fungicides | . . Animal-feeding stuffs | ||||||||
EA15 | EA20 | |||||||||||
. Cosmetics or shampoos | . Pharmaceuticals | |||||||||||
EA21 | EA22 | EA23 | EA24 | EA25 | EA26 | EA27 | EA28 | EA29 | EA30 | |||
. . acting on central nervous systems | . . acting on biological defence mechanisms | . . acting on circulatory organs | . . acting on hematopoietic organs bloods or body liquids | . . acting on digestive organs | . . acting on urogenital organs | . . acting on metabolic systems | . . acting on functions of tissue cells | . . acting on pathogenetic organisms | . . Hormone-like agents | |||
EA31 | EA34 | EA35 | EA36 | EA40 | ||||||||
. . Vaccines | . Materials for medical purposes | . Surfactants | . Detergents | . Photographic or printing materials | ||||||||
EA45 | EA50 | |||||||||||
. Electric or communication materials | . Analytical or diagnostic materials | |||||||||||
EA51 | EA52 | EA53 | EA54 | EA55 | EA60 | |||||||
. . Cancers or tumours | . . Infectious diseases | . . . Virus infections | . . Cell surface antigens | . . Substrates for enzyme activity measurements | . Others | |||||||
EA61 | EA62 | EA65 | ||||||||||
. . using chemical properties | . . Synthetic intermediates | . . using physical properties | ||||||||||
FA | FA00 PROCESS OF PREPARATION |
FA10 | ||||||||||
. by chemical syntheses | ||||||||||||
FA15 | FA16 | FA20 | ||||||||||
. . by cutting peptide bonds | . . . Hydrolysis | . . by formation of peptide bonds | ||||||||||
FA30 | ||||||||||||
. . . Liquid phase processes | ||||||||||||
FA31 | FA32 | FA33 | FA34 | FA40 | ||||||||
. . . . Stepwise elongation processes | . . . . Fragment condensation processes | . . . Solid phase processes | . . . . Automatic syntheses | . . . Processes for forming peptide bonds | ||||||||
FA41 | FA42 | FA43 | FA44 | FA50 | ||||||||
. . . . Active ester processes | . . . . Mixed acid anhydride processes | . . . . Azide processes | . . . . Dicyclohexylcarbodiimide (DCC) processes | . . by chemical modifications other than cutting or forming peptide bonds | ||||||||
FA51 | FA52 | FA53 | FA57 | FA58 | FA59 | FA60 | ||||||
. . . of nitrogen-terminal amino groups or carbon-terminal carboxyl groups | . . . of amino acid side chains | . . . of non-amino acid components | . . Protection of functional groups | . . . Amino groups | . . . Carboxyl groups | . . . Other side chain functional groups | ||||||
FA61 | FA65 | FA67 | FA70 | |||||||||
. . Removal of protecting groups | . Denaturation | . Regeneration or reactivation | . Enzyme processes | |||||||||
FA71 | FA72 | FA73 | FA74 | FA80 | ||||||||
. by organisms | . . Cell culture or tissue culture | . . Fermentation processes | . . Gene recombinations | . Immobilisation processes | ||||||||
FA81 | FA82 | FA83 | FA84 | |||||||||
. . by covalent bonds | . . by adsorption | . . by crosslinking | . . by encapsulation into lattices | |||||||||
GA | GA00 SEPARATION, PURIFICATION, OR STABILISATION |
GA01 | GA05 | GA06 | GA10 | |||||||
. Extraction or solubilisation | . Precipitation | . . Salting out | . Ultrafiltration | |||||||||
GA15 | GA20 | |||||||||||
. Centrifugation | . by adsorption | |||||||||||
GA21 | GA22 | GA23 | GA24 | GA25 | GA26 | GA30 | ||||||
. . Chromatography | . . . Gel chromatography | . . . Ion-exchange chromatography | . . . Hydroxyapatite chromatography | . . . Reverse phase chromatography | . . . Affinity chromatography | . Electrophoresis | ||||||
GA31 | GA32 | GA33 | GA40 | |||||||||
. . Polyacrylamide gel electrophoresis | . . Isoelectric focusing | . . Two-dimensional electrophoresis | . Crystallisation | |||||||||
GA45 | ||||||||||||
. Stabilisation | ||||||||||||
HA | HA00 PHYSICOCHEMICAL PROPERTY |
HA01 | HA02 | HA03 | HA04 | HA05 | HA06 | HA07 | HA10 | |||
. Molecular weights (MW) | . . MW <= 1000 | . . 1000 < MW <= 5000 | . . 5000 < MW <= 10000 | . . 10000 < MW <= 50000 | . . 50000 < MW <= 100000 | . . 100000 < MW | . Isoelectric points (PI) | |||||
HA11 | HA12 | HA13 | HA14 | HA15 | HA16 | HA17 | HA18 | HA19 | HA20 | |||
. . PI <= 2.0 | . . 2.0 < PI <= 3.0 | . . 3.0 < PI <= 4.0 | . . 4.0 < PI <= 5.0 | . . 5.0 < PI <= 6.0 | . . 6.0 < PI <= 7.0 | . . 7.0 < PI <= 8.0 | . . 8.0 < PI <= 9.0 | . . 9.0 < PI <= 10.0 | . . 10.0 < PI <= 11.0 | |||
HA21 | HA30 | |||||||||||
. . 11.0 < PI | . Solubility | |||||||||||
HA31 | HA32 | |||||||||||
. . soluble in water | . . soluble in organic solvents |